skip to Main Content

Closeup of molecules Istari Oncology to Participate in Upcoming Virtual Investor Conferences LEARN MORE Closeup of molecules Istari Oncology Initiates Its Phase I/II Sub-Study Evaluating PVSRIPO in Patients with Head and Neck Cancer LEARN MORE Breaking News: PVSRIPO Receives Fast Track Designation in Advanced Melanoma LEARN MORE Jamie Iudica Joins Istari Oncology as Chief Manufacturing Officer LEARN MORE Closeup of molecules Breaking News:
Istari Oncology Honored as
"Best Early Stage Product Development Company" by the Triangle Business Journal
LEARN MORE
PVSRIPO Phase 1
Melanoma Trial
Published in JITC
LEARN MORE
FDA Clears IND for LUMINOS-103 Basket Trial for PVSRIPO LEARN MORE First Patient Dosed in LUMINOS-102 LEARN MORE Closeup of molecules New Study Shows PVSRIPO Leads to Robust, Polyfunctional
T Cells
LEARN MORE
Closeup of molecules Orphan status granted to PVSRIPO for advanced melanoma LEARN MORE Closeup of molecules Watch our latest video about PVSRIPO's mechanism of action VIEW HERE

Istari Oncology to Participate in Upcoming Virtual Investor Conferences LEARN MORE Breaking News: PVSRIPO Receives Fast Track Designation in Advanced Melanoma LEARN MORE Jamie Iudica Joins Istari Oncology as Chief Manufacturing Officer LEARN MORE Closeup of molecules Istari Oncology to Present Data from its PVSRIPO Immunotherapy Platform at the American Society of Clinical Oncology 2021 Annual Meeting LEARN MORE Closeup of molecules Breaking News:
Istari Oncology Honored as
“Best Early Stage Product Development Company” by Triangle Business Journal
LEARN MORE
PVSRIPO Phase 1 Melanoma Trial Published in JITC LEARN MORE FDA Clears IND for LUMINOS-103 Basket Trial for PVSRIPO LEARN MORE First Patient Dosed in LUMINOS-102 LEARN MORE Closeup of molecules New Study Shows PVSRIPO Leads to Robust, Polyfunctional T Cells LEARN MORE Closeup of molecules Orphan status granted to PVSRIPO for advanced melanoma LEARN MORE Closeup of molecules Watch our latest video about PVSRIPO's mechanism of action VIEW HERE

Revolutionizing cancer care.

PVSRIPO is an investigational intratumoral immunotherapy based on the Sabin type-1 polio vaccine. Learn more about how this novel approach to viral immunotherapy could provide a safer, more effective approach to immune activation against cancer.

Reshaping the Standard of Care for the Treatment of Cancer

Istari Oncology is a clinical-stage biotechnology company focused on developing and commercializing groundbreaking immuno-oncology therapies with the potential to improve the standard of care for a wide range of solid tumors, including glioblastoma and melanoma.

TECHNOLOGIES IN CLINICAL DEVELOPMENT

Polio Virus Sabin-Rhinovirus Poliovirus (PVSRIPO)

Antibody Toxin Conjugates (ATCs)

Orange circle with white brain icon inside

OUR SCIENCE

Find out more about our breakthrough PVSRIPO platform

Green circle with white arrows inside

PIPELINE

For more on how our technologies are advancing

Fuchsia circle with white newspaper icon inside

NEWS

Access the latest updates and research

Back To Top
×Close search
Search